Orchard announces $150 million to advance gene therapy pipeline

Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, has announced the completion of an oversubscribed $150 million Series C financing to advance gene therapy pipeline.

Proceeds from the Series C financing will be used to progress Orchard’s three most advanced clinical programs:

  1. OTL-101 for adenosine deaminase severe combined immunodeficiency (ADA-SCID),
  2. OTL-200 for metachromatic leukodystrophy (MLD)
  3. OTL-103 for Wiskott–Aldrich syndrome (WAS) towards registration and commercialisation.

The funding will also support the clinical and preclinical development of the company’s rare disease gene therapy pipeline.

Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management LP, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, LP, as well as additional U.S. based healthcare focused funds.

Mark Rothera, president and CEO of Orchard said, “We are thrilled to have such strong support from both new and existing investors in this financing round. The quality of this investor syndicate is a testament to the confidence we have built among our stakeholders, based on the substantial progress of Orchard’s clinical and preclinical programs since our Series B round last year.”

Frank Thomas, CFO and chief business officer of Orchard, said “This financing provides Orchard with additional capital to rapidly progress our most advanced clinical programs to commercialisation. We are advancing our pipeline of potentially transformative gene therapies in primary immune deficiencies and neurometabolic disorders to reach patients as quickly as possible.”

Elise Wang, Principal at Deerfield Management said, “Orchard has made an impressive transition from a start-up company to an emerging leader in gene therapy for rare diseases by building a comprehensive, industry-leading, portfolio of ex vivo gene therapies and assembling a highly experienced team. We are pleased to have led this round of financing. We believe the company has generated compelling clinical data on products which have the potential to become breakthrough treatments for patients.”